Coloplast stock faces a lower JPMorgan target at DKK 377.00

Published on 09/29/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coloplast stock faces JPMorgan's DKK 377.00 target after a September 9 downgrade. The 9M report showed 6% organic growth and a 26% EBIT margin.

Pop-Art-Comic-Illustration einer lächelnden Pflegekraft mit medizinischen Pflegeprodukten — Coloplast A/S (DK0060448595) als Medizintechnik-Firma inspiriert diese farbenfrohe Pop-Art-Comic-Szene mit einer freundlichen Pflegekraft dargestellt, Illustration mit AI erstellt.

Coloplast (ISIN DK0060448595) stock was trading at DKK 417.00 on Nasdaq Copenhagen on September 29, 2026, down 0.90% from the previous close of DKK 420.80. The key valuation signal remains JPMorgan's September 9 downgrade from Neutral to Underweight and its target cut from DKK 484.00 to DKK 377.00, as reported by Investing.com.

Growth holds while margins narrow

Coloplast's latest reported period covers the nine months ended June 30, 2026. In the third quarter, organic revenue growth was 6%, while EBIT increased 5% in constant currencies to DKK 1,929 million, according to Via Ritzau on August 18, 2026.

The reported EBIT margin was 26%, compared with 28% a year earlier. The comparison matters because the growth rate held up, but profitability narrowed by 2 percentage points as Kerecis and currency effects weighed on the quarter.

Biologics is the counterweight

Biologics revenue fell 6% in Q3 2025/26, and the segment recorded a negative 5% EBIT margin before purchase price allocation amortization. That weakness offset stronger performances in Chronic Care and Urology.

For the first nine months, reported revenue increased 3% and reported EBIT declined 2% year over year, while organic growth reached 6%. Coloplast kept its full-year 2025/26 guidance for 5% to 6% organic revenue growth and 5% EBIT growth in constant currencies, according to Via Ritzau.

Next results set for November 3

The next scheduled reporting date is November 3, 2026, according to Coloplast's financial calendar published through MFN on September 24, 2026. That report is likely to be the next major test of management's growth assumptions and the new CEO's strategic priorities.

Coloplast stock stays below its yearly high

At DKK 417.00 on September 29, 2026, Coloplast stock stood 44.25% below its 52-week high of DKK 748.00 and above its low of DKK 369.70. The market capitalization was DKK 94.0 billion and trading volume was 33,995 shares.